The latest featured news from Pituitary World News
Today, Dr. Scott Struthers talks to PWN about paltusotine, their new once-a-day oral drug candidate. Crinetics recently published results from their Pathfinder 1 study, which recently completed phase 3 of the clinical trial.
Learn about Grand Rounds and watch episode one. PWN’s Pituitary Grand Rounds is a bit different. It attempts to bring the best of the classic GR programs to modern times and use them to bring to light pituitary cases in a dynamic, accessible way so people can learn more about the intricacies of these conditions. No two are the same, and there is always something worth noting in each.
San Diego, California-based Crinetics Pharmaceutical announced today that its novel investigational drug paltusotine maintained IGf-1 levels in patients who switched from monthly injectables
From the desk of J. D. Faccinetti, co-founder – We are big fans; collaboration works. Our experience and research suggest that when collaboration between organizations is strong, learning improves, and outcomes…
From Lewis S. Blevins Jr., M.D. cofounder – Lehrer and others published a nice review on the role of stereotactic radiosurgery (SRS) for functioning and nonfunctioning pituitary adenomas. They reviewed several studies focusing on both the beneficial and adverse effects of the treatment of different tumor subtypes.